Aspirin is a widely used medication known primarily for its pain-relieving, anti-inflammatory, and blood-thinning properties. When considering its safety for people with Alzheimer’s disease (AD), the issue becomes complex due to the nature of Alzheimer’s pathology and the potential risks and benefits of aspirin use in this population.
Alzheimer’s disease is characterized by the accumulation of amyloid-beta plaques and tau protein tangles in the brain, leading to progressive cognitive decline. Additionally, many patients with AD have cerebrovascular changes, including cerebral amyloid angiopathy (CAA), where amyloid deposits accumulate in the walls of cerebral blood vessels. This condition increases the risk of cerebral microbleeds and hemorrhages[1].
Aspirin’s primary mechanism involves inhibiting platelet aggregation, which reduces the risk of blood clots and is beneficial in preventing cardiovascular events such as heart attacks and strokes. However, this blood-thinning effect also increases the risk of bleeding, including intracerebral hemorrhage. In patients with Alzheimer’s disease, especially those with CAA, this bleeding risk is a significant concern. The fragile blood vessels affected by amyloid deposits are more prone to bleeding, and aspirin could exacerbate this risk[1].
Clinical evidence on aspirin use specifically in Alzheimer’s patients is limited and somewhat mixed. Some studies have explored the role of anti-inflammatory drugs in AD due to the inflammatory component of the disease. Aspirin, as a nonsteroidal anti-inflammatory drug (NSAID), was hypothesized to potentially slow cognitive decline by reducing neuroinflammation. However, large clinical trials have not demonstrated a clear cognitive benefit of aspirin in AD patients. Moreover, the increased risk of bleeding complications often outweighs any potential benefits[1].
The decision to use aspirin in people with Alzheimer’s disease often depends on individual cardiovascular risk factors. For example, if a patient has a history of cardiovascular disease or stroke, aspirin might be prescribed to reduce those risks despite the potential bleeding risk. In such cases, careful monitoring is essential. Conversely, for AD patients without cardiovascular indications, routine aspirin use is generally not recommended due to the lack of proven cognitive benefit and the bleeding risk[1].
Other medications, such as statins, have been studied for their potential neuroprotective effects in Alzheimer’s disease. Statins may influence cognition by modulating cholesterol metabolism and reducing neuroinflammation, with some evidence suggesting slower cognitive decline in statin users. However, these findings do not directly support aspirin use but highlight the complexity of managing AD with medications that affect vascular and inflammatory pathways[2].
In summary, aspirin is not universally safe or recommended for all people with Alzheimer’s disease. Its use must be individualized, weighing cardiovascular benefits against the increased risk of cerebral bleeding, particularly in those with cerebral amyloid angiopathy. Current authoritative sources emphasize caution and the need for personalized medical advice when considering aspirin therapy in AD patients[1][2].
Sources:
[1] Frontiers in Aging Neuroscience, 2025. Cerebral amyloid angiopathy: a narrative review.
[2] Journal of Alzheimer’s Disease Reports, 2025. Statins, cholesterol and cognition at the time of Alzheimer’s disease.
